Anavex Life Sciences (AVXL) SEC Filings: History & Chart

Anavex Life Sciences Corp.(AVXL)

Biotechnology · New York City, NY

$1.67+0.02 (+1.52%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Anavex Life Sciences Corp.

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.

New York City, NY

34 employees

www.anavex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Terrie Kellmeyer

View full financials

Form	Filing Date	Accepted	Document
3	Oct 5, 2026	Oct 5, 2026	View filing
3	Oct 5, 2026	Oct 5, 2026	View filing
4	Sep 28, 2026	Sep 28, 2026	View filing
8-K	Sep 28, 2026	Sep 28, 2026	View filing
DFAN14A	Sep 21, 2026	Sep 18, 2026	View filing
DFAN14A	Sep 18, 2026	Sep 18, 2026	View filing
DFAN14A	Sep 17, 2026	Sep 17, 2026	View filing
DEFA14A	Sep 15, 2026	Sep 15, 2026	View filing
DFAN14A	Sep 15, 2026	Sep 15, 2026	View filing
DEFA14A	Sep 14, 2026	Sep 14, 2026	View filing
DFAN14A	Sep 10, 2026	Sep 10, 2026	View filing
DFAN14A	Sep 10, 2026	Sep 9, 2026	View filing
DFAN14A	Sep 9, 2026	Sep 9, 2026	View filing
8-K	Sep 9, 2026	Sep 9, 2026	View filing
DEFA14A	Sep 8, 2026	Sep 8, 2026	View filing
DEFA14A	Sep 4, 2026	Sep 4, 2026	View filing
DFAN14A	Sep 4, 2026	Sep 3, 2026	View filing
DFAN14A	Sep 3, 2026	Sep 2, 2026	View filing
8-K	Sep 2, 2026	Sep 2, 2026	View filing
DFAN14A	Sep 2, 2026	Sep 2, 2026	View filing
DEFA14A	Sep 1, 2026	Sep 1, 2026	View filing
DEFA14A	Aug 31, 2026	Aug 31, 2026	View filing
10-Q	Aug 28, 2026	Aug 28, 2026	View filing
10-Q	Aug 28, 2026	Aug 28, 2026	View filing
10-Q/A	Aug 28, 2026	Aug 28, 2026	View filing
10-K/A	Aug 28, 2026	Aug 28, 2026	View filing
DEFC14A	Aug 27, 2026	Aug 27, 2026	View filing
PRRN14A	Aug 27, 2026	Aug 26, 2026	View filing
8-K	Aug 25, 2026	Aug 25, 2026	View filing
DEFA14A	Aug 24, 2026	Aug 24, 2026	View filing

SEC Filings

Recent Filings